Aduro Biotech, Inc. announced a strategic reset to focus on Aduro's core strengths discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways. Aduro is partnered with Novartis for STING pathway activators in oncology, including ADU-S100 (MIW815).
Chinook Therapeutics, Inc.
Equities
KDNY
US16961L1061
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+22.94% | 27.87B | |
-17.74% | 20.95B | |
-15.96% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |